+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Lung Cancer Translational Research Grant Competition

Cancer Research Society

In Canada, lung cancer remains the leading cause of cancer-related deaths, yet it remains one of the most underfunded in terms of research. To address this major issue, the Cancer Research Society is investing $2 million in translational research on this disease.

This program will support 4 research projects aimed at:

Improving early detection of lung cancer
Developing more effective treatments
Understanding the mechanisms of resistance to current therapies

Budget

Each grant is limited to a maximum of $500,000 over a 3-year period.

Application process

A letter of intent is required for all applications. Selected applicants will be invited to submit a full application, which will be evaluated by a peer review committee.

AI Based Application Success Predictor

🔑 1. Top-Tier Scientific Excellence (Most Decisive)

CRS is strongly peer-review driven, so:

Clear, hypothesis-driven research is essential
Strong preliminary rationale (data helps but not always required)
Methodological rigor and reproducibility

👉 Weak science = immediate rejection, regardless of topic

🎯 2. Clear and Direct Cancer Relevance

Funded proposals:

Address core cancer problems, such as:
- Tumor biology
- Metastasis
- Resistance mechanisms
Or contribute to:
- Prevention
- Early detection
- Survivorship

👉 Indirect or loosely connected projects rarely succeed

🔄 3. Translational Potential (Critical Differentiator)

CRS prioritizes research that:

Bridges basic discovery → clinical application
Has a plausible path to:
- Biomarkers
- Therapeutic targets
- Clinical studies

👉 Pure basic science must still answer:
“How could this eventually benefit patients?”

🧬 4. Strong Mechanistic Insight

Winning proposals often:

Go beyond description → explain how and why
Focus on:
- Molecular pathways
- Genetic/epigenetic mechanisms

👉 Mechanistic depth is a major scoring advantage

⚖️ 5. Balanced Innovation (Novel but Feasible)

High-value proposals:
- Introduce new ideas or approaches
- But remain achievable within grant scope

👉 Overly risky without feasibility = rejected
👉 Too incremental = low scores

🤝 6. Interdisciplinary & Collaborative Strength

Higher success rates seen in:

Projects combining:
- Biology + clinical research
- Data science / AI + oncology
Multi-institution teams

👉 Collaboration signals broader impact and feasibility

🧪 7. Feasible Study Design & Clear Aims

Typically:
- 2–4 well-defined aims
Must include:
- Realistic timeline
- Logical experimental flow

👉 Vague or overcomplicated aims are a major weakness

👩‍🔬 8. Investigator Strength (Relative to Career Stage)

Senior investigators:
- Strong publication and funding track record
Early-career:
- Clear independence trajectory
- Strong mentorship

👉 CRS supports both, but credibility matters

🌍 9. Alignment with CRS Strategic Priorities

Higher success when aligned with:

Prevention and risk factors
Environmental exposures
Precision oncology
Survivorship

👉 Targeted calls significantly increase success odds

📈 10. Potential for Future Impact & Funding

CRS favors projects that:

Generate:
- High-impact publications
- Follow-up grants (CIHR, NIH, etc.)
Contribute long-term to cancer research

👉 Think of CRS as launchpad funding

📊 What Actually Wins (Practical Ranking)

🔥 Decisive factors:

Scientific excellence
Clear cancer relevance
Translational potential

⚖️ Major differentiators:

Mechanistic depth
Innovation + feasibility balance
Collaboration

📌 Supporting factors:

Study design clarity
Investigator credibility
Strategic alignment

💡 Insider Insight

Compared to other cancer funders:

Cancer Research Society sits between:
- AACR (science-heavy)
- ACS (impact + population)

👉 CRS expects:
“Strong mechanistic science with a believable path to real-world impact”

Specialties

Cancer

Eligibility Requirements

The principal investigator and co-applicants must hold a research position at a Canadian institution and be able to hold research funds at their institution.

Sponsor Details

Sponsor Institute/Organizations: Cancer Research Society

Sponsor Type: Corporate/Non-Profit

Address: 625 President-Kennedy Avenue Suite 402 Montreal QC H3A 3S5

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity